ReBio Pharma to Deliver Poster Presentation at Upcoming Association for Research in Vision and Ophthalmology Annual Meeting
May 3, 2024 – Turku, Finland – ReBio Pharma, a preclinical stage biotechnology company that has developed SiSu®, an injectable bioresorbable sustained release delivery platform for ophthalmic therapeutics, today announced that it will be delivering a poster presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 5-9 in Seattle, Washington, USA.
The poster highlights pre-clinical pharmacokinetics, safety, and tolerability data that indicates the ability to safely control intravitreal sustained release for varying durations via the company’s proprietary SiSu® technology platform. SiSu® is a phase-inverting anhydrous liquid polymer formulation that creates a semi-solid in-situ forming implant (ISFI) when injected into an aqueous environment. SiSu® is designed to steadily release effective levels of therapeutics while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required.
ReBio Pharma has several investigational therapeutics in its pipeline intended for delivery via the SiSu® platform, the first of which is RBLP, a twice-yearly intravitreally administered formulation of latanoprost for the treatment of mild-to-moderate primary open-angle glaucoma.
“We are excited to attend ARVO this year and present the results of this safety, tolerability, and pharmacokinetics study for our lead product for glaucoma, RBLP,” says Vinod Vijayakumar, CEO of ReBio Pharma. “This marks an important milestone for ReBio Pharma, as it is our first-ever public data presentation. We are looking forward to sharing the important work we’re doing with the broader ophthalmology community. We believe our drug delivery platform, SiSu®, has the potential to transform disease management for a broad range of indications and represents a step-change in versatility over currently available sustained release methods.”
Glaucoma is the second-leading cause of blindness worldwide, with 3 million Americans and more than 80 million people worldwide living with the condition. More broadly, the global ophthalmic disease therapeutics market was estimated at $38 billion in 2023 and is projected to grow at a compound annual growth rate of 8.3% from 2024 to 2030. Vision impairment is a significant financial burden globally, with the annual global cost of productivity loss estimated to be $411 billion. In the US, it is estimated that the economic cost of major vision problems will increase to $373 billion by 2050.
The study authors concluded that the SiSu® technology platform has the potential to enable the long-term release of chronically administered therapeutics, “which would reduce the need for frequent dosing of eyedrops, or the frequency of intravitreal injections, and helps address the dual challenges of compliance and persistence (e.g., in glaucoma and diabetic retinopathy patients)."
About ReBio Pharma
ReBio Pharma is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. SiSu® is designed to steadily release effective levels of therapeutics within the eye while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required. ReBio Pharma is leveraging Sisu® to create a new franchise to transform the standard of care in the treatment of vision-threatening chronic eye diseases. Discover more at www.rebiopharma.com.